Episode

Myra Ahmad (Founder & CEO of Mochi Health) - The future of GLP-1s

Podcast
Hims House
Published
Feb 12, 2026
Duration seconds
2652
Processing state
not_requested
Canonical source
https://podcasters.spotify.com/pod/show/jonathan-stern1/episodes/Myra-Ahmad-Founder--CEO-of-Mochi-Health---The-future-of-GLP-1s-e3evv8a
Audio
https://anchor.fm/s/10e9c0874/podcast/play/115391178/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-1-12%2F417953106-44100-2-501168a2124b7.mp3
JSON
/v1/public/podcasts/hims-house-7026583/episodes/myra-ahmad-founder-ceo-of-mochi-health-the-future-of-glp-1s
Markdown
/podcast/hims-house-7026583/myra-ahmad-founder-ceo-of-mochi-health-the-future-of-glp-1s.md

Actions

  • POST https://stenobird.com/v1/public/podcasts/hims-house-7026583/episodes/myra-ahmad-founder-ceo-of-mochi-health-the-future-of-glp-1s/transcription-requests
    Idempotently request low-priority transcript generation for this episode.
  • GET https://stenobird.com/podcast/hims-house-7026583/myra-ahmad-founder-ceo-of-mochi-health-the-future-of-glp-1s.md
    Read the agent-friendly Markdown representation of this episode resource.

Summary

In Episode 56 of Hims House, Jonathan Stern sits down with Myra Ahmad, founder and CEO of Mochi Health, to unpack where GLP-1s are headed - and how Mochi is building a broader telehealth marketplace around metabolic care. Myra explains Mochi’s pharmacy “marketplace” model and how she thinks about staying compliant with compounded GLP-1 pills amid increasing FDA scrutiny. They discuss oral vs. injectable GLP-1s, why pills may be an on-ramp but not a long-term winner for most patients, and what the Hims GLP-1 pill episode signals about enforcement and risk. Myra also outlines Mochi’s expansion beyond weight loss, including longevity and labs, and where AI can (and can’t) meaningfully replace humans in healthcare. The conversation closes with predictions on the next wave of GLP-1s. 00:00 - Sponsor: Mochi Health 01:56 - Mochi's compounded semaglutide pill 04:27 - Oral vs. injectable GLP-1s 11:25 - $HIMS GLP-1 pill blowback 17:19 - FDA enforcement risk and what could change 22:27 - Patents, “personalization,” and where compounders may get exposed 24:05 - Mochi's growth story 24:47 - Retatrutide 31:32 - Why the U.S. could resemble Canada's system 34:09 - AI in healthcare 37:40 - Labs, GRAIL, and prevention 41:01 - The next era of GLP-1s Disclaimer: This podcast is for informational and entertainment purposes only. Nothing discussed should be considered financial, investment, or legal advice. Always consult with a qualified professional before making financial decisions.